FOLH1 and neoplasm: 111In-JVZ-007-c-myc-his was evaluated in mice bearing PC-310 (PSMA+) and PC-3 (PSMA-) tumors, showing good and specific tumor targeting already at 4 h after injection, with low background intensity.